A Day Up For Palvella Therapeutics, Inc.
Tue, Feb 24, 2026 at 07:31 PM
Palvella Therapeutics, Inc. (PVLA:NASDAQ) rocketted at $120.41, a gain of 37.1%. On Tue, Feb 24, 2026, PVLA:NASDAQ touched a New 2-Week High of $120.41. The stock appeared on our News Catalysts scanner on Tue, Feb 24, 2026 at 05:23 PM in the 'PUBLIC OFFERING' category. From Wed, Feb 11, 2026, the stock recorded 62.50% Up Days and 55.56% Green Days
About Palvella Therapeutics, Inc. (PVLA:NASDAQ)
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics.
Top 10 Gainers:
- Edesa Biotech, Inc. (EDSA:NASDAQ), 67.96%
- Rich Sparkle Holdings Limited (ANPA:NASDAQ), 52.93%
- Brand Engagement Network, Inc. (BNAI:NASDAQ), 40.23%
- Clarivate Plc (CLVT:NYSE), 39.88%
- Ten-League International Holdings Limited (TLIH:NASDAQ), 37.74%
- Palvella Therapeutics, Inc. (PVLA:NASDAQ), 37.08%
- Founder Group Limited (FGL:NASDAQ), 34.26%
- Larimar Therapeutics, Inc. (LRMR:NASDAQ), 31.32%
- Gain Therapeutics, Inc. (GANX:NASDAQ), 31.1%
- Global Interactive Technologies, Inc. (GITS:NASDAQ), 30.9%